FDA OKs Subcutaneous Nivolumab in Advanced/Metastatic Solid Tumors
Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo).
Related Articles
Covey’s Eisenhower Matrix: An Essential Decision-Making Tool
Covey’s Eisenhower Matrix is a simple, foundational decision-making tool to help determine what you need to do now, later, or never. Download and print several…
Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors
Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.
Nurses recognised in 2025 New Year Honours
Community and primary care nurses are among the 1,200 people who have been recognised in the King’s New Year Honours list 2025.
Top 5 Stories from the 2024 San Antonio Breast Cancer Symposium
CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.
Factors that can enhance resilience in mental health nursing staff who work in high-secure forensic hospitals
Commentary on: Rooney, C, Pyer, M, & Campbell, J. Leaving it at the gate: A phenomenological exploration of resilience in mental health nursing staff in…
Consolidation Durvalumab Improves PFS in Unresectable NSCLC
Durvalumab improved progression-free survival in unresectable NSCLC patients without progression post-chemoradiotherapy, reducing disease progression risk by 25% compared to placebo.
Nursing staff ‘cannot wait’ until 2028 for long-term social care reform
The government has announced an independent commission to ‘rebuild’ adult social care and introduce reforms
The Official Podcast of AANP
NP Pulse: The Voice of the Nurse Practitioner® The American Association of Nurse Practitioners ® (AANP) NP Pulse: The Voice of the Nurse Practitioner ®…
How Monjuvi Plus Revlimid, Rituxan Work to Treat Follicular Lymphoma
The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.
Supporting people with dementia to navigate hospital admissions
Emma Hughes explains the benefits of her role as a Transitions of Care Admiral Nurse, helping people living with dementia and their families